Role of the extracellular matrix and its receptors in smooth muscle cell function: Implications in vascular development and disease

Current Opinion in Lipidology

Volumn 18, Issue 5, 2007, Pages 540-545

  Hultgårdh Nilsson, Anna ^a,b   Durbeej, Madeleine ^b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Atherosclerosis; Dystrophin glycoprotein complex; Integrins; Proteoglycans; VSMC

Indexed keywords

ALPHA4 INTEGRIN; ALPHA7 INTEGRIN; DECORIN; DYSTROPHIN; FIBULIN; INTEGRIN; NITRIC OXIDE; PERLECAN; PROTEOGLYCAN; SARCOGLYCAN; THROMBOSPONDIN 1; VERSICAN;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; CARDIOMYOPATHY; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; DISEASE COURSE; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; MUSCLE CONTRACTILITY; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR DISEASE;

ANIMALS; BLOOD VESSELS; DYSTROGLYCANS; EXTRACELLULAR MATRIX; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LAMININ; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; VASCULAR DISEASES;

ANIMALIA;

EID: 34648837952     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282ef77e9     Document Type: Review

References (62)

1. Hallmann R, Horn N, Selg M, et al. Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev 2005; 85:979-1000.
2. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2003; 84:767-801.
3. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev 2002; 12:349-361.
4. Segev A, Strauss BH. The role of perlecan in arterial injury angiogenesis. Cardivasc Res 2004; 63:603-610.
5. McEvan PA, Scott PG, Bishop PN, Bella J. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Structural Biol 2006; 155:294-305.
6. Shimizu-Hirota R, Sasamura H, Kuroda M, et al. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res 2004; 94:1067-1074.
7. Ström Å, Ahlqvist A, Franzén A, et al. Extracellular matrix components in atherosclerotic arteries of apo E/LDL receptor deficient mice: an immunohistochemical study. Histol Histopathol 2004; 19:337-347.
8. Riessen R, Fenchel M, Chen H, et al. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. Arterioscler Throm Vasc Biol 2001; 21:47-54.
9. Ström A, Olin AI, Aspberg A, Hultga° rdh-Nilsson A. Fibulin-2 is present in murine vascular lesions and is important for smooth muscle cell migration. Cardiovasc Res 2006; 69:755-763. This interesting paper demonstrates that fibulin-2 can be produced by VSMC as a response to injury. Together with versican it can regulate VSMC migration as a response to in-vitro injury.
10. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9:685-693.
11. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314:15-23.
12. Grazioli A, Alves CS, Konstantopoulos K, Yang JT. Defective blood vessel development and pericyte/pvSMC distribution in α4 integrin-deficient mouse embryos. Dev Biol 2006; 293:165-177.
13. Flintoff-Dye NL, Welser J, Rooney J, et al. Role for the α7β1 integrin in vascular development and integrity. Dev Dyn 2005; 234:11-21.
14. Kalluri R. Basement membranes: structure, assembly and role in tumor angiogenesis. Nat Rev cancer 2003; 3:422-433.
15. Ajani AE, Yan BP. The mystery of coronary artery spasm. Heart Lung Circ 2007; 16:10-15.
16. Beedle AM, Nienaber PM, Campbell KP. Fukutin-related protein associates with the sarcolemmal dystrophin-glycoprotein complex. J Biol Chem 2007; 282:16713-16717. This elegantly demonstrates that FKRP is present at the skeletal muscle cell surface where it coexists with dystroglycan in the native dystrophin-glycoprotein complex.
17. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006; 119:199-207.
18. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nature Rev Mol Cell Biol 2006; 7:762-773.
19. Goodwin FC, Muntoni F. Cardiac involvement in muscular dystrophies: molecular mechanisms. Muscle Nerve 2005; 32:577-588.
20. Straub V, Ettinger AJ, Durbeej M, et al. ε -Sarcoglycan replaces α-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. J Biol Chem 1999; 274:27989-27996.
21. Anastasi G, Cutroneo G, Sidoti A, et al. Sarcoglycan subcomplex expression in normal human smooth muscle. J Histochem Cytochem 2007; 16 Apr [Epub ahead of print].
22. Coral-Vazquez R, Cohn R, Moore SA, et al. Disruption of the sarcoglycansarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 1999; 98:465-474.
23. Durbeej M, Cohn RD, Hrstka RF, et al. Disruption of the β-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol Cell 2000; 5:141-151.
24. Cohn RD, Durbeej M, Moore SA, et al. Prevention of cardiomyopathy in mouse models lacking smooth muscle sarcoglycan-sarcospan complex. J Clin Invest 2001; 107:R1-R9.
25. Wheeler MT, Allikian MJ, Heydemann A, et al. Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycandeficient cardiomyopathy. J Clin Invest 2004; 113:668-675.
26. Lipskaia L, Pinet C, Fromes Y, et al. Mutation of δ-sarcoglycan is associated with Ca2+-dependent vascular remodelling in the syrian hamster. Am J Path 2007; 171:162-171. Data presented here suggest that mutations in the gene encoding δ-sarcoglycan result in increased plasma permeability to calcium, activation of the calcium-regulated transcription factor NFAT and subsequent mitochondrial aggregation, which leads to aberrant VSMC proliferation and apoptosis.
27. Durbeej M, Sawatzki S, Barresi R, et al. Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy. Proc Acad Natl Sci U S A 2003; 100:8910-8915.
28. Ito K, Kimura S, Ozasa S, et al. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Gen 2006; 15:2266-2275.
29. Hedin U, Roy J, Tran PK, et al. Control of smooth muscle cell proliferation - the role of the basement membrane. Thromb Haemost 1999; 82 (Suppl):23-26.
30. Tran P-K, Tran-Lundmark K, Soininen R, et al. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ Res 2004; 94:550-558.
31. Tran P-K, Agardh HE, Tran-Lundmark K, et al. Reduced perlecan expression and accumulation in human carotid atherosclerotic lesions. Atherosclerosis 2007; 190:264-270. This interesting study demonstrated a reduction of perlecan at both mRNA and protein levels in human atherosclerosis. The study is based on material from 44 patients.
32. Martinez-Lemus LA, Wu X, Wilson E, et al. Integrins as unique receptors for vascular control. J Vasc Res 2003; 40:211-233.
33. Hoshiga M, Alpers CE, Smith LL, et al. avb3 integrin expression in normal and atherosclerotic artery. Circ Res 1995; 77:1129-1135.
34. Chao J-T, Meininger GA, Patterson JL, et al. Regulation of α7-integrin expression in vascular smooth muscle injury-induced atherosclerosis. Am J Physiol Heart Circ Physiol 2004; 287:H381-H389.
35. 2+ channel and dystrophin expression after balloon injury in rat aortic cells. Cardiovasc Res 2001; 49:177-188.
36. Riessen R, Isner JM, Blessing E, et al. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994; 144:962-974.
37. Camejo G, Hurt-Camejo E, Eklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998; 139:205-222.
38. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-561.
39. Skålén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750-754.
40. Nakashima Y, Fujii H, Sumiyoshi S, et al. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007; 27:1159-1165. This describes an interesting study on early atherosclerosis in human coronary arteries. The data show that fatty streaks develop via extracellular deposition of lipids in association with proteoglycans.
41. Svensson L, Aszodi A, Reinholt FP, et al. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J Biol Chem 1999; 274:9636-9647.
42. Kalamajski S, Aspberg A, Oldberg Å. The decorin sequence SYIRIADTNIT binds collagen type I. J Biol Chem 2007; 282:16062-16067.
43. Ameye L, Aria D, Jepsen K, et al. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J 2002; 16:673-680.
44. Ezura Y, Hakravarti S, Oldberg Å, et al. Differential expression of lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons. J Cell Biol 2000; 151:779-788.
45. Talusan P, Bedri S, Yang S, et al. Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics 2005; 4:1350-1357.
46. Saika S, Shiraishi A, Saika S, et al. Role of lumican in the corneal epithelium during wound healing. J Biol Chem 2000; 275:2607-2612.
47. Yeh LK, Chen W-L, Li W, et al. Soluble lumican glycoprotein purified from human amniotic membrane promotes corneal epithelial wound healing. Investig Ophtalmol Vis Sci 2005; 46:479-486.
48. Onda M, Ishiwata T, Kawahara K, et al. Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis. Exp Mol Pathol 2002; 72:142-149.
49. Al Haj Zen A, Caligiuri G, Sainz J, et al. Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice. Atherosclerosis 2006; 187:31-39.
50. Patel MK, Lymn JS, Clunn GF, Huges AD. Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. Aterioscler Thromb Vasc Biol 1997; 17:2107-2114.
51. Okamoto M, Ono M, Uchiumi T, et al. Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells- transcriptional activation and messenger RNA stabilization. Biochim Biophys Acta 2002; 1574:24-34.
52. Roth JJ, Gahtan V, Brown JL, et al. Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. J Surg Res 1998; 74:11-16.
53. 1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastin in human coronary artery smooth muscle cells. Vasc Pharmacol 2006; 44:469-475.
54. Isenberg JS, Ridnour LA, Perruccio EM, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A 2005; 102:13141-13146.
55. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 2006; 71:785-793.
56. Isenberg JS, Yodo F, Matsumoto K-I, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric-oxide-mediated vascular smooth muscle relaxation. Blood 2007; 109:1945-1952. This is an elegant and extensive study demonstrating that TSP-1 modulates nitric oxide-dependent VSMC contractility. Furthermore, endogenously TSP-1 limits nitric oxide-mediated increases in perfusion of healthy and injured tissue.
57. Raman P, Krukovets I, Marinic TE, et al. Glycosylation mediated up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem 2007; 282:5704-5714.
58. Evanko SP, Johnson PY, Braun KR, et al. Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. Arch Biochem Biophys 2001; 394:29-38.
59. Ostberg O, Zhu P, Wight TN, Qwarnstrom EE. Fibronectin attachment is permissive for IL-1 mediated gene regulation. FEBS Lett 1998; 367:93-97.
60. Schönherr E, Kinsella MG, Wight TN. Genistein selectively inhibits platelet-derived growth factor stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch Biochem Biophys 1997; 339:353-361.
61. Lemire JM, Chan CK, Bressler S, et al. Inteleukin-1β selectively decreases the synthesis of versican by arterial smooth muscle cells. J Cell Biochem 2007; 101:753-766.
62. Rodriguez-Lee M, Östergren-Lundén G, Wallin B, et al. Fatty acids cause alterations of human arterial smooth muscle cell proteoglycans that increase the affinity for low-density lipoprotein. Arterioscler Thromb Vasc Biol 2006; 26:130-135. The study demonstrated the effect of NEFA on proteoglycans and their ability to bind low-density lipoprotein. It gives interesting information about several of the most important proteoglycans in early atherogenesis.